Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Circulating Tumor DNA Diagnostics Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Test Kits
1.2.3 Reagents
1.3 Market by Application
1.3.1 Global Circulating Tumor DNA Diagnostics Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospitals
1.3.3 Diagnostics Laboratories
1.3.4 Research Laboratories
1.3.5 Academic Research Institutes
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Circulating Tumor DNA Diagnostics Market Perspective (2018-2033)
2.2 Circulating Tumor DNA Diagnostics Growth Trends by Region
2.2.1 Global Circulating Tumor DNA Diagnostics Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Circulating Tumor DNA Diagnostics Historic Market Size by Region (2018-2023)
2.2.3 Circulating Tumor DNA Diagnostics Forecasted Market Size by Region (2024-2033)
2.3 Circulating Tumor DNA Diagnostics Market Dynamics
2.3.1 Circulating Tumor DNA Diagnostics Industry Trends
2.3.2 Circulating Tumor DNA Diagnostics Market Drivers
2.3.3 Circulating Tumor DNA Diagnostics Market Challenges
2.3.4 Circulating Tumor DNA Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Circulating Tumor DNA Diagnostics Players by Revenue
3.1.1 Global Top Circulating Tumor DNA Diagnostics Players by Revenue (2018-2023)
3.1.2 Global Circulating Tumor DNA Diagnostics Revenue Market Share by Players (2018-2023)
3.2 Global Circulating Tumor DNA Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Circulating Tumor DNA Diagnostics Revenue
3.4 Global Circulating Tumor DNA Diagnostics Market Concentration Ratio
3.4.1 Global Circulating Tumor DNA Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Circulating Tumor DNA Diagnostics Revenue in 2022
3.5 Circulating Tumor DNA Diagnostics Key Players Head office and Area Served
3.6 Key Players Circulating Tumor DNA Diagnostics Product Solution and Service
3.7 Date of Enter into Circulating Tumor DNA Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Circulating Tumor DNA Diagnostics Breakdown Data by Type
4.1 Global Circulating Tumor DNA Diagnostics Historic Market Size by Type (2018-2023)
4.2 Global Circulating Tumor DNA Diagnostics Forecasted Market Size by Type (2024-2033)
5 Circulating Tumor DNA Diagnostics Breakdown Data by Application
5.1 Global Circulating Tumor DNA Diagnostics Historic Market Size by Application (2018-2023)
5.2 Global Circulating Tumor DNA Diagnostics Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Circulating Tumor DNA Diagnostics Market Size (2018-2033)
6.2 North America Circulating Tumor DNA Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023)
6.4 North America Circulating Tumor DNA Diagnostics Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Circulating Tumor DNA Diagnostics Market Size (2018-2033)
7.2 Europe Circulating Tumor DNA Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023)
7.4 Europe Circulating Tumor DNA Diagnostics Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size (2018-2033)
8.2 Asia-Pacific Circulating Tumor DNA Diagnostics Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size by Region (2018-2023)
8.4 Asia-Pacific Circulating Tumor DNA Diagnostics Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Circulating Tumor DNA Diagnostics Market Size (2018-2033)
9.2 Latin America Circulating Tumor DNA Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023)
9.4 Latin America Circulating Tumor DNA Diagnostics Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size (2018-2033)
10.2 Middle East & Africa Circulating Tumor DNA Diagnostics Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023)
10.4 Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Grail, Inc.
11.1.1 Grail, Inc. Company Detail
11.1.2 Grail, Inc. Business Overview
11.1.3 Grail, Inc. Circulating Tumor DNA Diagnostics Introduction
11.1.4 Grail, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.1.5 Grail, Inc. Recent Development
11.2 Guardant Health, Inc.
11.2.1 Guardant Health, Inc. Company Detail
11.2.2 Guardant Health, Inc. Business Overview
11.2.3 Guardant Health, Inc. Circulating Tumor DNA Diagnostics Introduction
11.2.4 Guardant Health, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.2.5 Guardant Health, Inc. Recent Development
11.3 Biodesix, Inc.
11.3.1 Biodesix, Inc. Company Detail
11.3.2 Biodesix, Inc. Business Overview
11.3.3 Biodesix, Inc. Circulating Tumor DNA Diagnostics Introduction
11.3.4 Biodesix, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.3.5 Biodesix, Inc. Recent Development
11.4 Exosome Diagnostics
11.4.1 Exosome Diagnostics Company Detail
11.4.2 Exosome Diagnostics Business Overview
11.4.3 Exosome Diagnostics Circulating Tumor DNA Diagnostics Introduction
11.4.4 Exosome Diagnostics Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.4.5 Exosome Diagnostics Recent Development
11.5 Freenome Inc.
11.5.1 Freenome Inc. Company Detail
11.5.2 Freenome Inc. Business Overview
11.5.3 Freenome Inc. Circulating Tumor DNA Diagnostics Introduction
11.5.4 Freenome Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.5.5 Freenome Inc. Recent Development
11.6 LungLife AI, Inc.
11.6.1 LungLife AI, Inc. Company Detail
11.6.2 LungLife AI, Inc. Business Overview
11.6.3 LungLife AI, Inc. Circulating Tumor DNA Diagnostics Introduction
11.6.4 LungLife AI, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.6.5 LungLife AI, Inc. Recent Development
11.7 Inivata Ltd.
11.7.1 Inivata Ltd. Company Detail
11.7.2 Inivata Ltd. Business Overview
11.7.3 Inivata Ltd. Circulating Tumor DNA Diagnostics Introduction
11.7.4 Inivata Ltd. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.7.5 Inivata Ltd. Recent Development
11.8 Personal Genome Diagnostics, Inc.
11.8.1 Personal Genome Diagnostics, Inc. Company Detail
11.8.2 Personal Genome Diagnostics, Inc. Business Overview
11.8.3 Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Introduction
11.8.4 Personal Genome Diagnostics, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.8.5 Personal Genome Diagnostics, Inc. Recent Development
11.9 CellMax Life
11.9.1 CellMax Life Company Detail
11.9.2 CellMax Life Business Overview
11.9.3 CellMax Life Circulating Tumor DNA Diagnostics Introduction
11.9.4 CellMax Life Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023)
11.9.5 CellMax Life Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Circulating Tumor DNA Diagnostics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Test Kits
Table 3. Key Players of Reagents
Table 4. Global Circulating Tumor DNA Diagnostics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 5. Global Circulating Tumor DNA Diagnostics Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Circulating Tumor DNA Diagnostics Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Circulating Tumor DNA Diagnostics Market Share by Region (2018-2023)
Table 8. Global Circulating Tumor DNA Diagnostics Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 9. Global Circulating Tumor DNA Diagnostics Market Share by Region (2024-2033)
Table 10. Circulating Tumor DNA Diagnostics Market Trends
Table 11. Circulating Tumor DNA Diagnostics Market Drivers
Table 12. Circulating Tumor DNA Diagnostics Market Challenges
Table 13. Circulating Tumor DNA Diagnostics Market Restraints
Table 14. Global Circulating Tumor DNA Diagnostics Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Circulating Tumor DNA Diagnostics Market Share by Players (2018-2023)
Table 16. Global Top Circulating Tumor DNA Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor DNA Diagnostics as of 2022)
Table 17. Ranking of Global Top Circulating Tumor DNA Diagnostics Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Circulating Tumor DNA Diagnostics Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Circulating Tumor DNA Diagnostics Product Solution and Service
Table 21. Date of Enter into Circulating Tumor DNA Diagnostics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Circulating Tumor DNA Diagnostics Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Circulating Tumor DNA Diagnostics Revenue Market Share by Type (2018-2023)
Table 25. Global Circulating Tumor DNA Diagnostics Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 26. Global Circulating Tumor DNA Diagnostics Revenue Market Share by Type (2024-2033)
Table 27. Global Circulating Tumor DNA Diagnostics Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Circulating Tumor DNA Diagnostics Revenue Market Share by Application (2018-2023)
Table 29. Global Circulating Tumor DNA Diagnostics Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 30. Global Circulating Tumor DNA Diagnostics Revenue Market Share by Application (2024-2033)
Table 31. North America Circulating Tumor DNA Diagnostics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 32. North America Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 33. North America Circulating Tumor DNA Diagnostics Market Size by Country (2024-2033) & (US$ Million)
Table 34. Europe Circulating Tumor DNA Diagnostics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. Europe Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 36. Europe Circulating Tumor DNA Diagnostics Market Size by Country (2024-2033) & (US$ Million)
Table 37. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 38. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size by Region (2024-2033) & (US$ Million)
Table 40. Latin America Circulating Tumor DNA Diagnostics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 41. Latin America Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 42. Latin America Circulating Tumor DNA Diagnostics Market Size by Country (2024-2033) & (US$ Million)
Table 43. Middle East & Africa Circulating Tumor DNA Diagnostics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Country (2018-2023) & (US$ Million)
Table 45. Middle East & Africa Circulating Tumor DNA Diagnostics Market Size by Country (2024-2033) & (US$ Million)
Table 46. Grail, Inc. Company Detail
Table 47. Grail, Inc. Business Overview
Table 48. Grail, Inc. Circulating Tumor DNA Diagnostics Product
Table 49. Grail, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023) & (US$ Million)
Table 50. Grail, Inc. Recent Development
Table 51. Guardant Health, Inc. Company Detail
Table 52. Guardant Health, Inc. Business Overview
Table 53. Guardant Health, Inc. Circulating Tumor DNA Diagnostics Product
Table 54. Guardant Health, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023) & (US$ Million)
Table 55. Guardant Health, Inc. Recent Development
Table 56. Biodesix, Inc. Company Detail
Table 57. Biodesix, Inc. Business Overview
Table 58. Biodesix, Inc. Circulating Tumor DNA Diagnostics Product
Table 59. Biodesix, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023) & (US$ Million)
Table 60. Biodesix, Inc. Recent Development
Table 61. Exosome Diagnostics Company Detail
Table 62. Exosome Diagnostics Business Overview
Table 63. Exosome Diagnostics Circulating Tumor DNA Diagnostics Product
Table 64. Exosome Diagnostics Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023) & (US$ Million)
Table 65. Exosome Diagnostics Recent Development
Table 66. Freenome Inc. Company Detail
Table 67. Freenome Inc. Business Overview
Table 68. Freenome Inc. Circulating Tumor DNA Diagnostics Product
Table 69. Freenome Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023) & (US$ Million)
Table 70. Freenome Inc. Recent Development
Table 71. LungLife AI, Inc. Company Detail
Table 72. LungLife AI, Inc. Business Overview
Table 73. LungLife AI, Inc. Circulating Tumor DNA Diagnostics Product
Table 74. LungLife AI, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023) & (US$ Million)
Table 75. LungLife AI, Inc. Recent Development
Table 76. Inivata Ltd. Company Detail
Table 77. Inivata Ltd. Business Overview
Table 78. Inivata Ltd. Circulating Tumor DNA Diagnostics Product
Table 79. Inivata Ltd. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023) & (US$ Million)
Table 80. Inivata Ltd. Recent Development
Table 81. Personal Genome Diagnostics, Inc. Company Detail
Table 82. Personal Genome Diagnostics, Inc. Business Overview
Table 83. Personal Genome Diagnostics, Inc. Circulating Tumor DNA Diagnostics Product
Table 84. Personal Genome Diagnostics, Inc. Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023) & (US$ Million)
Table 85. Personal Genome Diagnostics, Inc. Recent Development
Table 86. CellMax Life Company Detail
Table 87. CellMax Life Business Overview
Table 88. CellMax Life Circulating Tumor DNA Diagnostics Product
Table 89. CellMax Life Revenue in Circulating Tumor DNA Diagnostics Business (2018-2023) & (US$ Million)
Table 90. CellMax Life Recent Development
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Circulating Tumor DNA Diagnostics Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Circulating Tumor DNA Diagnostics Market Share by Type: 2022 VS 2033
Figure 3. Test Kits Features
Figure 4. Reagents Features
Figure 5. Global Circulating Tumor DNA Diagnostics Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 6. Global Circulating Tumor DNA Diagnostics Market Share by Application: 2022 VS 2033
Figure 7. Hospitals Case Studies
Figure 8. Diagnostics Laboratories Case Studies
Figure 9. Research Laboratories Case Studies
Figure 10. Academic Research Institutes Case Studies
Figure 11. Circulating Tumor DNA Diagnostics Report Years Considered
Figure 12. Global Circulating Tumor DNA Diagnostics Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 13. Global Circulating Tumor DNA Diagnostics Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 14. Global Circulating Tumor DNA Diagnostics Market Share by Region: 2022 VS 2033
Figure 15. Global Circulating Tumor DNA Diagnostics Market Share by Players in 2022
Figure 16. Global Top Circulating Tumor DNA Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor DNA Diagnostics as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Circulating Tumor DNA Diagnostics Revenue in 2022
Figure 18. North America Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 19. North America Circulating Tumor DNA Diagnostics Market Share by Country (2018-2033)
Figure 20. United States Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Canada Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Circulating Tumor DNA Diagnostics Market Share by Country (2018-2033)
Figure 24. Germany Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. France Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. U.K. Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Italy Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Russia Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Nordic Countries Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Circulating Tumor DNA Diagnostics Market Share by Region (2018-2033)
Figure 32. China Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Japan Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. South Korea Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Southeast Asia Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. India Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Australia Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Circulating Tumor DNA Diagnostics Market Share by Country (2018-2033)
Figure 40. Mexico Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Brazil Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Circulating Tumor DNA Diagnostics Market Share by Country (2018-2033)
Figure 44. Turkey Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Saudi Arabia Circulating Tumor DNA Diagnostics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Grail, Inc. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2018-2023)
Figure 47. Guardant Health, Inc. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2018-2023)
Figure 48. Biodesix, Inc. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2018-2023)
Figure 49. Exosome Diagnostics Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2018-2023)
Figure 50. Freenome Inc. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2018-2023)
Figure 51. LungLife AI, Inc. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2018-2023)
Figure 52. Inivata Ltd. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2018-2023)
Figure 53. Personal Genome Diagnostics, Inc. Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2018-2023)
Figure 54. CellMax Life Revenue Growth Rate in Circulating Tumor DNA Diagnostics Business (2018-2023)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed